Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

T cell gene therapy - Cell Genesys

Drug Profile

T cell gene therapy - Cell Genesys

Alternative Names: Anti-HIV T cell gene therapy

Latest Information Update: 12 Oct 2006

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cell Genesys
  • Class Antivirals; Gene therapies
  • Mechanism of Action CD4 agonists; CD8 antigen stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Colorectal cancer; HIV-1 infections

Most Recent Events

  • 14 Aug 2001 Discontinued-II for HIV-1 infections in USA (IV-infusion)
  • 29 May 2001 Cell Genesys is seeking a collaborator for T cell gene therapy for HIV infection
  • 27 Sep 1999 Results of a clinical study has been added to the therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top